Cargando…

Myeloid dysregulation and therapeutic intervention in COVID-19

The dysregulation of myeloid cell responses is increasingly demonstrated to be a major mechanism of pathogenesis for COVID-19. The pathological cellular and cytokine signatures associated with this disease point to a critical role of a hyperactivated innate immune response in driving pathology. Uniq...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Runxia, Mao, Tianyang, Lu, Qiao, Tianjiao Su, Tina, Wang, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8576142/ https://www.ncbi.nlm.nih.gov/pubmed/34823995 http://dx.doi.org/10.1016/j.smim.2021.101524

Ejemplares similares

Molecular landscape and targeted therapy of acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2018)

Dysregulation of lung myeloid cells in COVID-19
por: Salomé, Bérengère, et al.
Publicado: (2020)

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment
por: Schulte-Schrepping, Jonas, et al.
Publicado: (2020)

SETBP1 dysregulation in congenital disorders and myeloid neoplasms
por: Coccaro, Nicoletta, et al.
Publicado: (2017)

Immune asynchrony in COVID-19 pathogenesis and potential immunotherapies
por: Zhou, Ting, et al.
Publicado: (2020)

Dysregulation of the Ubiquitin Proteasome System in Human Malignancies: A Window for Therapeutic Intervention
por: Fhu, Chee Wai, et al.
Publicado: (2021)

Risk and clinical outcomes of COVID-19 in patients with rheumatic diseases compared with the general population: a systematic review and meta-analysis
por: Wang, Qingxiu, et al.
Publicado: (2021)

Dysregulation of immunity in COVID-19 and SLE
por: Hejazian, Seyyed Sina, et al.
Publicado: (2022)

EVI1 dysregulation: impact on biology and therapy of myeloid malignancies
por: Birdwell, Christine, et al.
Publicado: (2021)

Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia
por: Basilico, Silvia, et al.
Publicado: (2017)

Neuropsychiatric manifestations of COVID-19, potential neurotropic mechanisms, and therapeutic interventions
por: Han, Ying, et al.
Publicado: (2021)

Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity
por: Sturley, Stephen L., et al.
Publicado: (2020)

RARG Gene Dysregulation in Acute Myeloid Leukemia
por: Conserva, Maria Rosa, et al.
Publicado: (2019)

Immune dysregulation and system pathology in COVID-19
por: Jamal, Muhammad, et al.
Publicado: (2021)

Dysregulated Bradykinin: Mystery in the Pathogenesis of COVID-19
por: Tabassum, Aisha, et al.
Publicado: (2022)

The role of dysregulated immune responses in COVID-19 pathogenesis
por: Tahaghoghi-Hajghorbani, S, et al.
Publicado: (2020)

Dysregulated Interferon Response Underlying Severe COVID-19
por: Lopez, LeAnn, et al.
Publicado: (2020)

Zinc dysregulation in cancers and its potential as a therapeutic target
por: Wang, Jie, et al.
Publicado: (2020)

Inflammatory pathways in COVID‐19: Mechanism and therapeutic interventions
por: Jiang, Yujie, et al.
Publicado: (2022)

Therapeutic Strategies to Target Calcium Dysregulation in Alzheimer’s Disease
por: Calvo-Rodriguez, Maria, et al.
Publicado: (2020)

Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
por: Du, Danyu, et al.
Publicado: (2022)

Editorial: Cardiorenal dysregulation in endocrine disorders: innovative mechanisms and therapeutic interventions
por: Shawky, Noha M., et al.
Publicado: (2023)

Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia
por: Liu, Qiao, et al.
Publicado: (2020)

The recent progress of myeloid‐derived suppressor cell and its targeted therapies in cancers
por: Ren, Ruiyang, et al.
Publicado: (2023)

Hallmarks of immune response in COVID-19: Exploring dysregulation and exhaustion
por: Mazzoni, Alessio, et al.
Publicado: (2021)

Dysregulation of miR-200s clusters as potential prognostic biomarkers in acute myeloid leukemia
por: Zhou, Jing-dong, et al.
Publicado: (2018)

Dysregulation of Rho GTPases in Human Cancers
por: Jung, Haiyoung, et al.
Publicado: (2020)

Dysregulations of Functional RNA Modifications in Cancer, Cancer Stemness and Cancer Therapeutics
por: Uddin, Mohammad Burhan, et al.
Publicado: (2020)

A comprehensive review on potential therapeutics interventions for COVID-19
por: Chugh, Heerak, et al.
Publicado: (2021)

Dysregulated miRNAs as Biomarkers and Therapeutical Targets in Neurodegenerative Diseases
por: Gentile, Giulia, et al.
Publicado: (2022)

Implications of Tau Dysregulation in Huntington’s Disease and Potential for New Therapeutics
por: Mees, Isaline, et al.
Publicado: (2023)

T-cell dysregulation in COVID-19
por: Kalfaoglu, Bahire, et al.
Publicado: (2021)

Potential Therapeutic Effects of Meditation for Treating Affective Dysregulation
por: Leung, Natalie T. Y., et al.
Publicado: (2014)

Dysregulation of Protein S in COVID-19
por: Sim, Martha M.S., et al.
Publicado: (2022)

EZH2 dysregulation: Potential biomarkers predicting prognosis and guiding treatment choice in acute myeloid leukaemia
por: Chu, Ming‐qiang, et al.
Publicado: (2019)

Dysregulation of Human Somatic piRNA Expression in Parkinson’s Disease Subtypes and Stages
por: Zhang, Tianjiao, et al.
Publicado: (2022)

Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions
por: Wang, Bin, et al.
Publicado: (2022)

ROS and miRNA Dysregulation in Ovarian Cancer Development, Angiogenesis and Therapeutic Resistance
por: Stieg, David C., et al.
Publicado: (2022)

Telomeric repeat-containing RNA is dysregulated in acute myeloid leukemia
por: Catto, Luiz Fernando B., et al.
Publicado: (2023)

The Implications of Cannabinoid-Induced Metabolic Dysregulation for Cellular Differentiation and Growth
por: Podinić, Tina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_864tbpqtqe2m62uqal5aa4vrvd